How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
55
MRNA Quote, Financials, Valuation and Earnings
Last price:
$44.08
Seasonality move
:
19.69%
Day range:
$43.43 - $46.34
52-week range:
$22.28 - $55.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.65x
P/B ratio:
1.85x
Volume:
11M
Avg. volume:
13.3M
1-year change:
7.38%
Market cap:
$17.2B
Revenue:
$3.2B
EPS (TTM):
-$8.06
Analysts' Opinion
-
Consensus RatingModerna, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 18 Hold ratings, and 1 Sell rating.
-
Price Target DownsideAccording to analysts' consensus price target of $38.80, Moderna, Inc. has an estimated downside of -14.57% from its current price of $44.07.
-
Price Target UpsideAccording to analysts, the highest upside price target is $135.00 representing 206.33% upside increase from its current price of $44.07.
Fair Value
-
According to the consensus of 21 analysts, Moderna, Inc. has -14.57% downside to fair value with a price target of $38.80 per share.
MRNA vs. S&P 500
-
Over the past 5 trading days, Moderna, Inc. has underperformed the S&P 500 by -9.83% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Moderna, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Moderna, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Moderna, Inc. reported revenues of $1B.
Earnings Growth
-
Moderna, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Moderna, Inc. reported earnings per share of -$0.51.
Enterprise value:
13.4B
EV / Invested capital:
--
Price / LTM sales:
7.65x
EV / EBIT:
--
EV / Revenue:
6.03x
PEG ratio (5yr expected):
-0.14x
EV / Free cash flow:
-5.05x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$869M
Return On Assets:
-23.33%
Net Income Margin (TTM):
-139.61%
Return On Equity:
-30.18%
Return On Invested Capital:
-27.85%
Operating Margin:
-25.59%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $9.1B | $5.1B | $2.2B | $1.9B | $1B | |
| Gross Profit | $2.9B | $3.1B | $869M | $1.3B | $757M | |
| Operating Income | -$2.7B | -$2.7B | -$3.5B | -$70M | -$260M | |
| EBITDA | -$2.2B | -$2.4B | -$3.3B | -$18M | -$208M | |
| Diluted EPS | -$9.34 | -$5.82 | -$8.06 | $0.03 | -$0.51 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $13.4B | $14.3B | $10.8B | $9.7B | $6.6B | |
| Total Assets | $20.9B | $26.1B | $19.5B | $15.8B | $12.1B | |
| Current Liabilities | $10B | $6.8B | $4.4B | $2.2B | $1.7B | |
| Total Liabilities | $10.8B | $8.1B | $6B | $3.9B | $2.8B | |
| Total Equity | $10.1B | $18B | $13.5B | $11.9B | $9.3B | |
| Total Debt | $561M | $1.2B | $1.4B | $1.3B | $717M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$2.1B | -$3.2B | -$2B | -$1.6B | -$847M | |
| Cash From Investing | $3.7B | $2B | $1.5B | $721M | $700M | |
| Cash From Financing | -$1.7B | -$50M | $9M | $11M | -$1M | |
| Free Cash Flow | -$2.7B | -$4B | -$2.7B | -$1.7B | -$880M | |
MRNA
Sector
Market Cap
$17.2B
$24.3M
Price % of 52-Week High
79.84%
50%
Dividend Yield
0%
0%
Shareholder Yield
0.76%
-1.67%
1-Year Price Total Return
7.38%
-21.43%
Beta (5-Year)
1.170
0.484
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$47.51
200-day SMA
Buy
Level
$28.59
Bollinger Bands (100)
Buy
Level
22.84 - 36.36
Chaikin Money Flow
Sell
Level
-5.4M
20-day SMA
Buy
Level
$41.05
Relative Strength Index (RSI14)
Buy
Level
58.63
ADX Line
Sell
Level
7.6
Williams %R
Neutral
Level
-48.7516
50-day SMA
Buy
Level
$33.29
MACD (12, 26)
Buy
Level
6.40
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Sell
Level
-192K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.774)
Buy
CA Score
(Annual)
Level (-0.2856)
Buy
Beneish M-Score
(Annual)
Level (-3.3998)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-0.007)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Stock Forecast FAQ
In the current month, MRNA has received 2 Buy ratings 18 Hold ratings, and 1 Sell ratings. The MRNA average analyst price target in the past 3 months is $38.80.
-
Where Will Moderna, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Moderna, Inc. share price will drop to $38.80 per share over the next 12 months.
-
What Do Analysts Say About Moderna, Inc.?
Analysts are divided on their view about Moderna, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Moderna, Inc. is a Sell and believe this share price will rise from its current level to $17.00.
-
What Is Moderna, Inc.'s Price Target?
The price target for Moderna, Inc. over the next 1-year time period is forecast to be $38.80 according to 21 Wall Street analysts, 2 of them rate the stock a Buy, 1 rates the stock a Sell, and 18 analysts rate the stock a Hold.
-
Is MRNA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Moderna, Inc. is a Hold. 18 of 21 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of MRNA?
You can purchase shares of Moderna, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Moderna, Inc. shares.
-
What Is The Moderna, Inc. Share Price Today?
Moderna, Inc. was last trading at $44.08 per share. This represents the most recent stock quote for Moderna, Inc.. Yesterday, Moderna, Inc. closed at $44.07 per share.
-
How To Buy Moderna, Inc. Stock Online?
In order to purchase Moderna, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get MRNA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MRNA
Sector
P/E ratio
--
23.33x
PEG ratio
-0.14x
-0.01x
P/B ratio
1.85x
1.78x
Price / LTM sales
7.65x
1.53x
Growth Metrics
MRNA
Sector
Revenue growth
-45.44%
4%
Earnings growth
-1673.01%
11.06%
Revenue (5-year growth)
121.86%
6.22%
Earnings forecast
-$2.27
-$0.19
Profitability
MRNA
Sector
Profitability FY 2024
$1.6B
$3M
Return on invested capital
-27.85%
-33.25%
Return on assets
-23.33%
-29.67%
Return on equity
-30.18%
-38.89%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
13
Estimated Next Earnings Date
Feb
5
Balance Sheet
MRNA
Sector
Total cash
$4.5B
$25M
Short term investments
$5.1B
$24.9M
Total assets
$14.1B
$72.5M
Long term debt
$717M
$2.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Sell
40
SHNY alert for Jan 31
MicroSectors Gold 3X Leveraged ETN [SHNY] is down 31.56% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
